Can-Fite BioPharma Ltd. Operating Income 2011-2026 | CANF

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Can-Fite BioPharma Ltd.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-8.13 M	-8.2 M	-10.1 M	-12.8 M	-14.1 M	-12 M	-5.41 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-5.41 M	-14.1 M	-10.1 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	-156 M	$ 2.08	-14.4 %	$ 214 M	USA
Acer Therapeutics ACER	-24.6 M	-	2.71 %	$ 14 M	USA
Altimmune ALT	-103 M	$ 4.2	-2.67 %	$ 298 M	USA
Apellis Pharmaceuticals APLS	55.4 M	$ 20.24	-3.44 %	$ 2.55 B	USA
Aprea Therapeutics APRE	-15.5 M	$ 0.88	-3.72 %	$ 3.18 M	USA
Aptevo Therapeutics APVO	-24.6 M	$ 7.2	-1.64 %	$ 1.99 M	USA
Aquestive Therapeutics AQST	-30.8 M	$ 4.1	2.37 %	$ 356 M	USA
AgeX Therapeutics AGE	-9.89 M	-	-10.17 %	$ 12.2 K	USA
Arcturus Therapeutics Holdings ARCT	-95.7 M	$ 8.35	1.46 %	$ 225 M	Israel
Ardelyx ARDX	-41 M	$ 6.37	-2.75 %	$ 1.54 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
argenx SE ARGX	-349 M	$ 756.71	-1.33 %	$ 25 B	Niderland
Armata Pharmaceuticals ARMP	-40.9 M	$ 10.91	1.58 %	$ 394 M	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
Arcutis Biotherapeutics ARQT	-12.2 M	$ 25.33	-6.1 %	$ 3.22 B	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Artelo Biosciences ARTL	-11.4 M	$ 1.15	-3.36 %	$ 2.32 M	USA
Arvinas ARVN	-118 M	$ 12.97	-2.3 %	$ 920 M	USA
Arrowhead Pharmaceuticals ARWR	98.3 M	$ 61.74	-2.42 %	$ 8.26 B	USA
Ascendis Pharma A/S ASND	-452 M	$ 231.56	-0.83 %	$ 5 B	Danmark
Actinium Pharmaceuticals ATNM	-42.1 M	$ 1.17	-0.85 %	$ 35.2 M	USA
Atossa Therapeutics ATOS	-31.4 M	$ 4.39	-0.9 %	$ 553 M	USA
Atara Biotherapeutics ATRA	-83.4 M	$ 5.01	-7.47 %	$ 37.5 M	USA
Aurinia Pharmaceuticals AUPH	33.2 M	$ 14.14	-0.21 %	$ 1.9 B	Canada
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Autolus Therapeutics plc AUTL	-241 M	$ 1.68	-1.75 %	$ 429 M	Britain
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Atea Pharmaceuticals AVIR	-193 M	$ 4.69	0.21 %	$ 395 M	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
AIkido Pharma AIKI	-11.5 M	-	1.93 %	$ 17.4 M	USA
Anavex Life Sciences Corp. AVXL	-51.4 M	$ 4.54	2.44 %	$ 387 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Axon Enterprise AXON	58.5 M	$ 570.5	5.18 %	$ 43.2 B	USA
Axsome Therapeutics AXSM	-167 M	$ 162.28	-0.98 %	$ 8.07 B	USA
Allena Pharmaceuticals ALNA	-47.6 M	-	3.16 %	$ 1.9 M	USA
Aytu BioScience AYTU	-7.83 M	$ 2.56	-0.58 %	$ 16.1 M	USA
Aileron Therapeutics ALRN	-65.1 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-65.4 M	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	-58.1 M	-	-	$ 2.17 B	USA